Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.-论文-万方医学网

作者： Andras,Heczey ^[1] ; Daofeng,Liu ^[1] ; Gengwen,Tian ^[2] ; Amy N,Courtney ^[1] ; Jie,Wei ^[1] ; Ekaterina,Marinova ^[1] ; Xiuhua,Gao ^[1] ; Linjie,Guo ^[1] ; Eric,Yvon ^[3] ; John,Hicks ^[2] ; Hao,Liu ^[4] ; Gianpietro,Dotti ^[5] ; Leonid S,Metelitsa ^[6]

作者单位： Texas Children's Cancer Center, Department of Pediatrics. ^[1] Department of Pathology and Immunology. ^[2] Center for Cell and Gene Therapy, and. ^[3] Division of Biostatistics, Dan L. Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX. ^[4] Department of Pathology and Immunology, Center for Cell and Gene Therapy, and. ^[5] Texas Children's Cancer Center, Department of Pediatrics, Department of Pathology and Immunology, Center for Cell and Gene Therapy, and. ^[6]

主题词 4-1BB配体(4-1BB Ligand);动物(Animals);抗原, CD1d(Antigens, CD1d);癌症疫苗(Cancer Vaccines);细胞系(Cell Line);细胞增殖(Cell Proliferation);细胞因子类(Cytokines);细胞毒性, 免疫(Cytotoxicity, Immunologic);神经节苷脂类(Gangliosides);移植物抗宿主病(Graft vs Host Disease);人类(Humans);免疫疗法(Immunotherapy);淋巴细胞活化(Lymphocyte Activation);巨噬细胞(Macrophages);小鼠(Mice);自然杀伤T细胞(Natural Killer T-Cells);肿瘤转移(Neoplasm Metastasis);神经母细胞瘤(Neuroblastoma);蛋白质结构, 三级(Protein Structure, Tertiary);受体, 抗原(Receptors, Antigen);逆转录病毒科(Retroviridae);转导, 遗传(Transduction, Genetic);治疗结果(Treatment Outcome)

DOI 10.1182/blood-2013-11-541235

PMID 25049283

发布时间 2021-10-21

检索历史清除

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

Blood

相似文献

Blood

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.

Blood

相似文献

Blood

相关期刊

检索历史清除